Emtricitabine

恩曲他滨

Report date: 2022/12/07 17:51:52
NME

Base Information

Drug NameEmtricitabine
Drug Alias Nameemtricitabina恩屈他滨曲西他滨Emtricitabinum恩曲西他平 +[11] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptase
Therapy Area/IndicationsCognitive DysfunctionAlzheimer DiseaseDementia +[4] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2003/07/02
Country/TerritoryCanadaPanamaUnited States +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncGilead Sciences Ireland UcBrown University +[6] 
Inactive CompaniesTriangle PharmaceuticalsGlaxo Wellcome IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsCognitive DysfunctionAlzheimer DiseaseDementia +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeJ05AF09
Related LinksWikipediaDrugBankKEGG